Cargando…

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials

BACKGROUND: Data have highlighted the potential bias introduced by withdrawal of inhaled corticosteroids at randomization in chronic obstructive pulmonary disease trials examining inhaled corticosteroids. Analyses were conducted to determine whether this was true of inhaled anticholinergic withdrawa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooper, Christopher B, Anzueto, Antonio, Decramer, Marc, Celli, Bartolome, Tashkin, Donald P, Leimer, Inge, Kesten, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152465/ https://www.ncbi.nlm.nih.gov/pubmed/21845038 http://dx.doi.org/10.2147/COPD.S17864

Ejemplares similares

Tiotropium HandiHaler(®) in the treatment of COPD: A safety review
por: Kesten, Steven, et al.
Publicado: (2009)

Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT(®) Trial
por: Halpin, David M. G., et al.
Publicado: (2011)

Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial
por: Tashkin, Donald P, et al.
Publicado: (2015)

Exacerbation frequency and course of COPD
por: Halpin, David MG, et al.
Publicado: (2012)

Adverse health consequences in COPD patients with rapid decline in FEV(1 )- evidence from the UPLIFT trial
por: Kesten, Steven, et al.
Publicado: (2011)

Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease
por: Celli, Bartolome R, et al.
Publicado: (2012)

Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes
por: Anzueto, A, et al.
Publicado: (2009)

Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium
por: Tashkin, Donald P
Publicado: (2010)

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
por: Hanania, Nicola A, et al.
Publicado: (2011)

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial
por: Wise, Robert, et al.
Publicado: (2015)

Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial
por: Celli, Bartolomé R., et al.
Publicado: (2016)

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial
por: Tashkin, Donald P., et al.
Publicado: (2018)

Tiotropium in asthma: back to the future of anticholinergic treatment
por: Bonini, Matteo, et al.
Publicado: (2017)

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
por: Hodder, Richard, et al.
Publicado: (2007)

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
por: Putcha, Nirupama, et al.
Publicado: (2022)

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
por: Singh, Dave, et al.
Publicado: (2016)

Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD
por: Tashkin, Donald P, et al.
Publicado: (2014)

Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial
por: Troosters, Thierry, et al.
Publicado: (2014)

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
por: Anzueto, Antonio, et al.
Publicado: (2020)

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations
por: Beeh, Kai-Michael, et al.
Publicado: (2009)

Safety and tolerability of inhalational anticholinergics in COPD
por: Sharafkhaneh, Amir, et al.
Publicado: (2013)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease
por: Miravitlles, Marc, et al.
Publicado: (2015)

Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients
por: Kesten, Steven, et al.
Publicado: (2008)

Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD
por: Cazzola, Mario, et al.
Publicado: (2023)

Skin reaction to inhaled tiotropium bromide: a case report
por: Incorvaia, Cristoforo, et al.
Publicado: (2011)

Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related
por: Koehorst-ter Huurne, Kirsten, et al.
Publicado: (2016)

Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation
por: Sunwoo, Jung, et al.
Publicado: (2017)

Tiotropium might improve survival in subjects with COPD at high risk of mortality
por: Burgel, Pierre-Régis, et al.
Publicado: (2014)

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
por: Anzueto, Antonio, et al.
Publicado: (2015)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
por: Bansal, Sandeep, et al.
Publicado: (2021)

Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study
por: Jahnz-Różyk, Karina, et al.
Publicado: (2015)

TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow
por: Mahler, Donald A, et al.
Publicado: (2021)

Tiotropium and exercise training in COPD patients: Effects on dyspnea and exercise tolerance
por: Ambrosino, Nicolino, et al.
Publicado: (2008)

Effect of Inhaled Tiotropium on Spirometric Parameters in Patients with Tuberculous Destroyed Lung
por: Yum, Ho-Kee, et al.
Publicado: (2014)

Pharmacokinetic Bioequivalence of Two Inhaled Tiotropium Bromide Formulations in Healthy Volunteers
por: Algorta, Jaime, et al.
Publicado: (2016)

A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD
por: Hilleman, Daniel E, et al.
Publicado: (2009)

Use of tiotropium bromide in an adolescent with adrenal suppression secondary to inhaled mometasone furoate
por: Hanna, Mariam, et al.
Publicado: (2014)

Bronchodilators in COPD: Impact of β-agonists and anticholinergics on severe exacerbations and mortality
por: Salpeter, Shelley R
Publicado: (2007)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2pde9uj8rji9apmtcjgnrkaaak